1 Amendments of Younous OMARJEE related to 2019/2073(DEC)
Amendment 10 #
12. Stresses that the Agency’s clients - pharmaceutical industry companies - pay for the procedure, not for the outcome of the Agency’s assessments; understands that, according to the Agency, its recommendations are made independently and therefore do not create conflicts of interest; notes with satisfaction that the Agency ensures that its scientific committee members and experts, staff and management board members, do not have any financial or other interests in the pharmaceutical industry; expresses concerns however about the potential conflict of interest in case of fee-financed agencies, where agencies have to rely on membership fees as their main source of income;